ABL1 and breast cancer: Indeed, inactivating mutations of TP53 were found in up to 30% of cases of BC-CML (reviewed in [20]) and loss of one Atm allele was sufficient for acceleration of the BC in a BCR-ABL transgenic mouse model of CML [45].